IMPACTT Team members, Microbiome research core.

IMPACTT MICROBIOME - TEAM MEMBERS

Platform 1
Gnotobiotic Animal Models & Intravital Vital

Platform 2
Human Cohort Design & Analysis

Platform 3
Microbial & Human Tissues Biobanks

Dr. Kathy McCoy
Director, Lead

Dr. Paul Kubes
Lead

Dr. Philippe Gros
Co-lead

Dr. Anita Kozyrskyj
Lead

Dr. Marie-Claire Arrieta
Co-lead

Dr. Joe Harrison
Co-Lead

Dr. Karen Madsen
Lead

Platform 4
Functional OMICS

Platform 5
Computational Development

Education Platform
Training & Mentorship

Dr. Laura Sycuro
Lead

Dr. Ian Lewis
Co-Lead

Dr. Celia Greenwood
Lead

Dr. William Hsiao
Co-lead

Dr. Fiona Brinkman
Lead

Dr. Markus Geuking
Lead

Dr. Braedon McDonald
Co-Lead

Ethics expert

Sex & Gender expert

Dr. Diego Silva
IMPACTT Lead

Dr. Jayne Danska
IMPACTT Lead

PLATFORM 1 - Gnotobiotic animal Models to Elucidate Mechanism

KATHY MCCOY, PhD
IMPACTT Director and Platform 1 Lead

Dr. Kathy McCoy is a Professor in the Cumming School of Medicine at the University of Calgary. She obtained her PhD in Immunology from the Malaghan Institute of Medical Research at Otago University, Wellington, New Zealand. She completed her postdoctoral studies, and was a junior group leader, at the Institute of Experimental Immunology in Zürich, Switzerland. In 2006, she joined McMaster University as an Assistant Professor where she held a Canada Research Chair in Mucosal Immunology. From 2010–2016 she was an Assistant Professor in Mucosal Immunology in the Department of Clinical Research at the University of Bern in Switzerland. In 2016, she returned to Canada as a Professor in the Cumming School of Medicine and the director of the International Microbiome Center at the University of Calgary, where she continues her research on host-microbial interactions with a focus on early life. Dr. McCoy is interested in the interplay between the gut microbiota and the immune systems, both innate and adaptive. Using germ-free and gnotobiotic mouse models, her research group aims to understand how exposure to intestinal microbes in early life can educate and regulate the development of the immune system, and how this can impact susceptibility to immune-mediated diseases such as allergy and autoimmunity.

PAUL KUBES, PhD
Platform 1 Co-Lead

Dr. Paul Kubes is a Professor in the Cumming School of Medicine at the University of Calgary, and is the Founding Director of the Snyder Institute for Chronic Diseases. He also holds a Canada Research Chair in Leukocyte Recruitment in Inflammatory Disease. Dr. Kubes has received numerous awards including the CIHR Investigator of the Year in 2011 for his work on how the brain affects immunity. He has also received the Alberta Science and Technology Award and the Henry Friesen Award. His research has been published in high impact science journals such as Cell, Science, and Nature, as well as clinical journals such as The Lancet and translational journals such as the Journal of Clinical Investigation. His latest work has uncovered a key role for peritoneal cavity macrophages in healing visceral organs. He has done work for CIHR, having participated in numerous review committees as a member of the CIHR Governing Council, and he is presently chair of the college chairs. He is on the editorial board of JCI and JEM and co-chaired the Gairdner Research Committee.

PHILIPPE GROS, PhD
Platform 1 Co-Lead

Dr. Philippe Gros obtained his PhD in Experimental Medicine from McGill University. Following his postdoctoral training at Massachusetts General Hospital and MIT, he joined the Department of Biochemistry at McGill in 1985, where he has been a full Professor since 1994. He is a member of the Centre for the Study of Host Resistance and the Goodman Cancer Research Centre, is the Director of the Complex Traits Program, and is the Vice-Dean (Health Research) of the Faculty of Medicine at McGill. His main area of investigation concerns the genetic analysis of susceptibility to infections, pre-disposition to neural tube defects, and models of carcinogen-induced cancer. Dr. Gros has been an International Scholar of the Howard Hughes Medical Institute, a Distinguished Scientist of the Canadian Institutes of Health Research (CIHR), and a James McGill Professor. He has received the Wilder Penfield Prize for Health Sciences (Prix du Québec), the Canada Council Killam Prize for Health Research, and is a fellow of the Royal Society of Canada. Dr. Gros acts as an advisor for several organizations, including the Burroughs Wellcome Fund, CIHR, and the Bill and Melinda Gates Foundation. Dr. Gros is the co-founder of PhageTech and Emerillon Therapeutics (Xenon).

PALOMA ARAUJO CAVALCANTE, MSc
Platform 1 Laboratory Technician

Paloma’s primary role for IMPACTT is to culture and identify bacteria from the human microbiome and assist with the gnotobiotic mouse repository. She has a BSc in Pharmacy from the Federal University of Ceara, Brazil, and a MSc in Veterinary Medicine from the University of Calgary. During her MSc degree, she studied the role of antimicrobial peptides in an infectious model of mouse mastitis. In her spare time, Paloma loves to spend time with family and friends, biking and playing board games.

HELVIRA CAVALCANTE MELO, PhD
Platform 1 Research Technician

As a lab technician, Dr. Melo supports and assists in the operation of the Laboratory’s research program and the International Microbiome Centre. She has a BSc in Pharmacy, and a MSc and PhD in Pharmacology from the Federal University of Ceara, Brazil. Her research focused on the screening of natural essential oils as an option for the treatment of anxiety and depression. In her free time, Dr. Melo loves to spend time with her husband and kids. She also loves to cook and photograph Alberta’s beautiful landscapes.

PLATFORM 2 - HUMAN COHORT DESIGN AND ANALYSIS PLATFORM

ANITA KOZYRSKYJ, PhD
Platform 2 Lead

Dr. Anita Kozyrskyj is a Professor of Pediatrics at the University of Alberta. She is a Principal Investigator (PI) of the SyMBIOTA (Synergy in Microbiota) research program, which investigates early life determinants in the development of the infant gut microbiota. She is also a PI of the CHILD (Canadian Healthy Infant Longitudinal Development) birth cohort study. SyMBIOTA was funded by one of 7 team grants from the first CIHR Microbiome Initiative in 2010. Dr. Kozyrskyj’s SyMBIOTA program has generated 40 papers and 2 book chapters. Her first infant gut microbiota paper on cesarean delivery received the 2014 CMAJ Bruce Squires Award for the most influential publication. Her paper on infant gut microbiota and food sensitization were presented to the US National Academies of Sciences, Engineering, and Medicine Committee on Food Allergy. She is associate editor of the Journal of Developmental Origins of Health and Disease and was co-editor of the 2016 special issue on “The Gut Microbiome and Immunity: How it is Shaped in Early Life.”

MARIE-CLAIRE ARRIETA, PhD
Platform 2 Co-Lead

Dr. Marie-Claire Arrieta is an Assistant Professor in the Department of Physiology and Pharmacology at the University of Calgary. Her research examines the interactions between the early-life gut microbiome and the infant’s immune system. Her research program is framed around a translational approach, in which samples collected from children undergoing clinical care or enrolled in birth cohort studies are used to characterize the microbial alterations (dysbiosis) associated with asthma and asthma risk. Her research group also examines the causality and mechanistic underpinnings of these associations in well-established mouse models of allergic airway inflammation, placing her research at the interface between clinical studies and experimental animal work.

PLATFORM 3 - MICROBIAL AND HUMAN TISSUE REPOSITORY

KAREN MADSEN, PhD
Platform 3 Lead

Dr. Karen Madsen is a Professor of Medicine at the University of Alberta. She is Director of the “Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)”. After receiving her BSc (Hon) and MSc degrees in Biochemistry at the University of Manitoba, she completed a PhD at the University of Calgary in the area of gastrointestinal physiology. The primary focus of her research is the relationships between the host and its resident microbiota, with specific interests in the role of microbes in inflammatory bowel diseases and metabolic disorders. The goal of her research program is to gain a mechanistic understanding of environmental and dietary influences on host-microbial interactions in order to design effective therapies to treat human disease based on manipulation of the gut microbiome. She is carrying out both clinical and basic research studies using dietary interventions, fecal microbial transplantation, and probiotic/ prebiotic therapy to treat metabolic disorders and inflammatory bowel disease along with mechanistic studies to examine how the host responds to microbial manipulation.

JOE HARRISON, PhD
Platform 3 Co-Lead

Dr. Joe Harrison is an Associate Professor in the Department of Biological Sciences at the University of Calgary. Dr. Harrison is passionate about microbiology, genetics, and biochemistry, and seeks to better understand chronic infectious diseases and to devise new ways to defeat them. He holds a Tier II Canada Research Chair in Biofilm Microbiology and Genomics. He is also a member of the Snyder Institute for Chronic Diseases, and is the chair of the Biofilm Research Group at the University of Calgary. During his PhD, Harrison had a lead role in developing and commercializing the MBECTM assay, which is used for biofilm antimicrobial susceptibility testing. This technology was commercialized to create a spinoff company acquired in 2006 by Innovotech Incorporated, which is now listed on the Toronto Stock Exchange.

SHIRIN AFROJ, MSc
Platform 3 Laboratory Technician

Shirin Afroj is a technologist at the University of Calgary, Department of Biological Sciences. In November 2020, Shirin joined Dr. Joe Harrison’s lab as a technician and lab manager. There, Shirin maintains the Alberta Microbiota Repository and assists with pilot projects for IMPACTT. Shirin graduated from the University of Regina with a MSc in Biology with a specialization in environmental microbiology. She also obtained a MSc in Biology from Dhaka University in Bangladesh, with a specialization in environmental microbiology. Previously, Shirin worked as a Laboratory Technologist in the Department of Medicine at the University of Calgary, and as a Research Officer in the virology laboratory of ICDDR,B, an international research centre in Bangladesh. Shirin has extensive experience in microbiology and molecular biology gained from working on diverse projects such as bacterial biofilms and clinical drug trials.

PLATFORM 4 - FUNCTIONAL OMICS

LAURA SYCURO, PhD
Platform 4 Lead

Dr. Laura Sycuro is an Assistant Professor at the University of Calgary in the Department of Microbiology, Immunology and Infectious Diseases. She is also one of the principal investigators of a new Albertan initiative that aims to understand how the maternal microbiome, both in pregnancy and in the early stages of microbial transmission to a newborn, impacts the lifelong health of children.
The broad goal of her research program is to harness the microbiome to promote maternal and child health. Her lab is working to advance the precision with which we define the composition of the microbiome and mechanistically link its species, strains, and genes to health outcomes. This work is unfolding in two directions: 1) Technology development that deepens our understanding of the microbiome’s pan-genomic content and fluidity 2) Identification of important genes that are funnelled into interdisciplinary functional studies. Her lab is also part of a collaborative team investigating how new vaccines that modulate the upper respiratory tract (URT) microbiota (by preventing common yet potentially pathogenic bacteria from colonizing) can affect the ecology and stability of the microbial community.

IAN LEWIS, PhD
Platform 4 Co-Lead

Dr. Ian Lewis, is an Assistant Professor and Alberta Innovates Translational Health Chair in Metabolomics at the Department of Biological Sciences at the University of Calgary. Lewis earned a PhD in Biochemistry from the University of Wisconsin-Madison and completed his postdoctoral training at Princeton University. He was recruited by the University of Calgary to launch a research program that harnesses state-of-the-art technology to detect and combat infectious diseases. As a part of this program, Dr. Lewis built the Calgary Metabolomics Research Facility (CMRF), an analytical lab that specializes in unravelling the complex host-pathogen metabolic interactions that occur during infections. Recently, he partnered with Calgary Laboratory Services to launch a suite of new diagnostic tools and treatment practices that may significantly reduce the number of people who die from infections.

OLABISI COKER, PhD
Platform 4 Research Associate

Dr. Olabisi Coker is a Metagenomic Research Associate at the International Microbiome Centre (IMC) and the Snyder Institute for Chronic Diseases at the University of Calgary. Dr. Coker holds a PhD in Microbiology with molecular biology skills and experience in bioinformatics. She has a keen interest in understanding the roles of the human microbiome and has demonstrated this by pioneering studies that unravelled potential contributions of gut microbes including bacteria, fungi, and archaea in gastrointestinal diseases such as colorectal cancer, non-alcoholic fatty liver disease, and gastric cancer, using human samples and animal models. Dr. Coker currently operates the microbiome-focused service platform of the IMC, specializing in shotgun and amplicon metagenomics, from client relations to sample handling through sequencing and bioinformatics. She also applies her skills in developing protocols and specialized workflows to meet the needs of IMC/IMPACTT research, operations, and services.

DOMINIQUE BIHAN, PhD
Platform 4 Research Associate

More about Dr. Bihan coming soon…

PLATFORM 5 - COMPUTATIONAL DEVELOPMENT FOR MULTI-OMIC LINKAGES

CELIA GREENWOOD, PhD
Platform 5 Lead

Dr. Celia Greenwood is a Senior Investigator at the Lady Davis Institute at the Jewish General Hospital in Montreal, QC, Canada, and a Professor in the Faculty of Medicine and Health Sciences at McGill University. In 2019, she was awarded a James McGill Professorship. As a statistician, she focuses her research on developing and applying statistical methodology for analysis of genetic and genomic data. Her recent methodological work focuses on dimension reduction and prediction with high dimensional data, analysis of DNA methylation data, and data integration. Applications of her methods have been used to improve understanding of multiple phenotypes and diseases, including osteoporosis, rheumatic diseases, cognitive ability, and cancer. Dr. Greenwood is also the Graduate Program Director of the new doctoral program “Quantitative Life Sciences” at McGill. She is a co-Director of the Ludmer Centre for Neuro informatics and Mental Health at McGill, focusing on integration of brain imaging, genetic, and epigenetic data to better understand mental health. From 2015 to 2017, she served on the Board of Directors of the International Genetic Epidemiology Society and is now its President.

FIONA BRINKMAN, PhD
Platform 5 Co-Lead

Dr. Fiona Brinkman is a Distinguished Professor in Bioinformatics and Genomics at Simon Fraser University (SFU), most known for R&D of widely used software that aids more integrative, systems-based analyses of microbe and human genomics/transcriptomics data. She leads CHILDdb data integration, to enable more integrative analysis of diverse CHILD Cohort Study data, including microbiome data, and she co-leads development of the IRIDA platform, which is now used as the primary platform for Canada’s Public Health Agency to track infectious disease outbreaks using combined epidemiological, lab and genomics/metagenomics data. She co-coordinates two large consortiums, involving researchers from 15 countries, enabling better genomic data sharing in an ethical framework. She has a strong interest in developing more preventative, sustainable approaches for disease control, using microbiome data as a sentinel for animal or ecosystem health, and also in bioinformatics education and mentoring young scientists. She is on several committees and boards, including chairing the Scientific Advisory Board for the European Nucleotide Archive. Her awards include a TR100 award from MIT, a “World’s Most Influential Scientific Minds” recognition from Thompson Reuters, and most recently she became a Fellow of the Royal Society of Canada.

WILLIAM HSIAO, PhD
Platform 5 Co-Lead

Dr. William Hsiao is an Associate Professor in the Faculty of Health Sciences at Simon Fraser University (SFU). He is an affiliate scientist at the BC Centre for Disease Control Public Health Laboratory (BCCDC PHL) and at Canada’s Michael Smith Genome Sciences Centre. He is also a genomic consultant with the BC Ministry of Agriculture Animal Health Centre. Before joining SFU, Dr. Hsiao was the chief bioinformatician at the BCCDC PHL and an Associate Professor at the University of British Columbia. He completed his PhD at SFU under Dr. Fiona Brinkman’s supervision, and a postdoctoral fellowship in Dr. Claire Fraser’s laboratory at the University of Maryland School of Medicine. His research focuses on developing bioinformatics applications and using next generation sequencing technologies to study microbial pathogens and microbiomes. He has participated in several genomic and metagenomic projects and is currently leading the effort to develop a bioinformatics platform to use whole genome sequencing to facilitate public health infectious disease outbreak investigations. This will be achieved by integrating data from genomic sequencing, clinical records, laboratory test results, and epidemiological investigations using semantic web technologies. Overall, his research aims to improve our understanding of the pathogens that make us sick and the microbiota that keep us healthy.

EDUCATION & MENTORSHIP

MARKUS GEUKING, PhD
Education Lead

Dr. Markus Geuking, IMPACTT Education lead, is an Associate Professor at the University of Calgary’s Cumming School of Medicine. He is a member of the Department of Microbiology, Immunology and Infectious Diseases as well as the Snyder Institute for Chronic Diseases. Dr. Geuking obtained his PhD in Immunology from the Federal Institute of Technology in Zurich (Switzerland) where he worked in the lab of Nobel Prize Laureate Professor Rolf Zinkernagel. He began his work on host-microbial immune interactions using germ-free and gnotobiotic models during his postdoctoral studies at McMaster University (Hamilton, Canada). He then continued this work as a research associate at the University of Bern (Switzerland) before joining the University of Calgary in 2016. Markus Geuking has over 30 peer-reviewed publications in journals such as Science and Immunity. He has received the AbbVie IBD Grant (2015), the Lutz Zwillenberg Award (2012), and the Swiss National Science Foundation Ambizione Grant (2010).

BRAEDON MCDONALD, MD, PhD
Education Co-Lead

Dr. Braedon McDonald, MD, PhD, FRCPC (Int Med), FRCPC (Crit Care) is an Assistant Professor of Critical Care Medicine at the University of Calgary’s Cumming School of Medicine and a member of the Snyder Institute for Chronic Diseases. Dr. McDonald earned a degree in microbiology and immunology at McGill University, followed by an MD and PhD in immunology at the University of Calgary. He completed his residency training in Internal Medicine at the University of British Columbia before returning to the University of Calgary to complete his subspecialty fellowship training in adult Critical Care Medicine, as well as a postdoctoral fellowship in microbiome research with Dr. Kathy McCoy at the International Microbiome Centre. His research program focuses on translational and discovery science in the area of microbiome-immune interactions in infection and critical illness, combining germ-free/gnotobiotic mouse models with high-resolution multi-dimensional immune analysis including in vivo (intravital) imaging and mass cytometry.

SYDNEY MORGAN, PhD
Education & Communication Coordinator

Dr. Sydney Morgan received her PhD in Biology from the University of British Columbia, Okanagan in 2019, where she studied the fungal and bacterial communities in wine fermentations under Dr. Daniel Durall. Her postdoctoral research was conducted at the University of California San Diego under Dr. Louise Laurent, where her focus was split between clinical COVID-19 research and investigating the microbiome in pregnancy. Dr. Morgan has long been passionate about science education and communication, and was a lecturer at Okanagan College where she designed and taught a course for a new Viticulture Technician Diploma program. She has given multiple guest lectures on topics ranging from SARS-CoV-2 to fungal hyphal growth, been an invited speaker at four industry conferences, and has won numerous speaking awards.

SEX & GENDER

JAYNE DANSKA , PhD
Sex & Gender Champion

Dr. Jayne Danska, IMPACTT Sex & Gender champion, was raised in New York City, and educated at Kenyon College, Cornell University, and Stanford University. She holds The Anne and Max Tanenbaum Chair in Molecular Medicine, is a Senior Scientist at the Hospital for Sick Children, and is a Professor in the Faculty of Medicine at the University of Toronto with appointments in the Departments of Immunology and Medical Biophysics. Her research is focused on defining the mechanisms underlying immune-mediated diseases as well as the application of this knowledge to improve diagnosis, prevention, and treatment. Her lab works on the genetic and environmental causes of autoimmune diseases, particularly Type 1 diabetes (T1D), the molecular mechanisms of acute lymphoid leukemia (ALL), and innate immune surveillance of blood cancers. She leads multi-disciplinary projects that identify the roles of genetic and environmental factors in the rising rates of autoimmune diseases, as well as investigating how the intestinal microbiome modifies the inherited risk of autoimmunity using rodent models and longitudinal studies of at-risk children. Her work is also focused on the impact of sex as a key determinant of autoimmune diseases, many of which are far more prevalent in females. Dr. Danska and her collaborators also discovered an immune signaling pathway pivotal to the survival of human hematopoietic stem cells and leukemia stem cells that sustain leukemic growth. They have developed a biologic therapy to manipulate this axis to impair the survival of leukemia and other blood cell cancers that is now in clinical trials. Dr. Danska has an active research training program within her research group. She serves and chairs grant panels, and is co-executive lead of the Chairs of College of Reviewers at the Canadian Institutes of Health Research.

ETHICS

DIEGO SILVA, PhD
Ethics Lead

Dr. Diego Silva, IMPACTT Ethics Committee lead, is a Lecturer at Sydney Health Ethics at the University of Sydney, Australia. He is also an Adjunct Professor in the Faculty of Health Sciences, Simon Fraser University in British Columbia. His research focuses on the intersection of ethics, political theory, and public health, including microbiome research. Dr. Silva has held grants as Principle Investigator from the Canadian Institutes of Health Research (CIHR) and Genome BC. His peer-reviewed publications have appeared in top bioethics journals (e.g., Journal of Medical Ethics, Public Health Ethics, Bioethics), as well as highly-rated medical journals (e.g., Lancet, CMAJ). In 2016, Dr. Silva was awarded the Mark S. Ehrenreich Prize in Healthcare Ethics Research by the International Association of Bioethics and the University of Southern California for the best paper in that year’s World Congress of Bioethics. Dr. Silva graduated in 2013 with a PhD in public health from the Dalla Lana School of Public Health, University of Toronto, and also holds an MA and BA (Honours) in philosophy from the University of Toronto.

IMPACTT ALUMNI

NICOLA PETT, BS
Platform 1 Laboratory Technician

During her stay with IMPACTT, Nicola started building the gnotobiotic mouse tissues repositories. She ensured the quality of the biobanking procedures was met, kept track of the samples, and was responsible for delivering samples to researchers upon request. Nicola obtained her Honours degree in Biomedical Science from the University of Queensland, Australia, where she focused on cell and molecular biology. After gaining experience in the field of cancer immunotherapy, her attention turned to the microbial world of the gastrointestinal tract when she joined the IMPACTT Team.

TAHSIN FERDOUS, MSc
Platform 2 Data Analyst

Tahsin Ferdous worked in Dr. Marie-Claire Arrieta’s lab at the University of Calgary as a biostatistician and data analyst. There, Tahsin applied her expertise to perform statistical analysis of microbiome data and write supporting documents. Tahsin graduated from the University of Calgary with a MSc in Biostatistics. She received a BSc (Hons) and another MSc degree in Statistics from Shahjalal University of Science & Technology, Sylhet, Bangladesh. She has applied statistical packages for simulated health data representing infectious persons in a sequence of hypothetical cities as well as RNA-sequencing data. She has a publication named “An Overview of RNA-seq Data Analysis” in the Journal of Biology and Life Science. She received the Queen Elizabeth II Diamond Jubilee Scholarship, as well as a research scholarship from the University of Calgary, in 2017. Tahsin has great enthusiasm for the field of bioinformatics, including working with microbiome data.

IMPACTT MICROBIOME - TEAM MEMBERS

PLATFORM 1 - Gnotobiotic animal Models to Elucidate Mechanism

KATHY MCCOY, PhDIMPACTT Director and Platform 1 Lead

PAUL KUBES, PhDPlatform 1 Co-Lead

PHILIPPE GROS, PhDPlatform 1 Co-Lead

PALOMA ARAUJO CAVALCANTE, MScPlatform 1 Laboratory Technician

HELVIRA CAVALCANTE MELO, PhD Platform 1 Research Technician

PLATFORM 2 - HUMAN COHORT DESIGN AND ANALYSIS PLATFORM

ANITA KOZYRSKYJ, PhDPlatform 2 Lead

MARIE-CLAIRE ARRIETA, PhDPlatform 2 Co-Lead

PLATFORM 3 - MICROBIAL AND HUMAN TISSUE REPOSITORY

KAREN MADSEN, PhDPlatform 3 Lead

JOE HARRISON, PhDPlatform 3 Co-Lead

SHIRIN AFROJ, MScPlatform 3 Laboratory Technician

PLATFORM 4 - FUNCTIONAL OMICS

LAURA SYCURO, PhDPlatform 4 Lead

IAN LEWIS, PhDPlatform 4 Co-Lead

OLABISI COKER, PhDPlatform 4 Research Associate

DOMINIQUE BIHAN, PhDPlatform 4 Research Associate

PLATFORM 5 - COMPUTATIONAL DEVELOPMENT FOR MULTI-OMIC LINKAGES

CELIA GREENWOOD, PhDPlatform 5 Lead

FIONA BRINKMAN, PhDPlatform 5 Co-Lead

WILLIAM HSIAO, PhDPlatform 5 Co-Lead

EDUCATION & MENTORSHIP

MARKUS GEUKING, PhDEducation Lead

BRAEDON MCDONALD, MD, PhDEducation Co-Lead

SYDNEY MORGAN, PhDEducation & Communication Coordinator

SEX & GENDER

JAYNE DANSKA , PhDSex & Gender Champion

ETHICS

DIEGO SILVA, PhDEthics Lead

IMPACTT ALUMNI

NICOLA PETT, BSPlatform 1 Laboratory Technician

TAHSIN FERDOUS, MScPlatform 2 Data Analyst

Share this:

Chair - Dr. McCoy

Chair Keynote Address #1 - Dr. Paul Kubes

Chair - Dr. Philippe Gros

Chair - Dr. Anita Kozyrskyj

Speaker - Dr. Marie-Claire Arrieta

Chair - Dr. Joe Harrison

Chair - Dr. Karen Madsen

Chair - Dr. Laura Sycuro

Chair - Dr. Ian Lewis

Chair - Dr. Celia Greenwood

Chair - Dr. William Hsiao

Chair - Dr. Fiona Brinkman

Chair - Dr. Markus Geuking

Chair - Dr. Braedon McDonald

Chair - Dr. Diego Silva